Manali Kamdar, MD, on Evaluating Liso-Cel in Mantle Cell Lymphoma by Lines of Therapy, Prior BTKi

Lisocabtagene maraleucel (liso-cel) has demonstrated its ability to yield durable complete responses in patients with heavily pretreated mantle cell lymphoma and was FDA-approved for this indication in May 2024.